Summary
The provided AI statements substantially exceed or diverge from the supplied label excerpts (which only cover all-cause mortality boxed warning/related content) and include many claims (e.g., liver toxicity, LFT monitoring frequency, specific clinical manifestations) that are not supported by the supplied prescribing information.
Category Scores
Accurate Statements
The FDA states that tigecycline has been associated with cases of liver failure, including fatalities.
Not supported by the provided label excerpts (only all-cause mortality boxed warning and related sections were supplied).
Unsupported Statements
Tigecycline is associated with liver toxicity.
No liver-toxicity content present in the provided label excerpts.
Tigecycline is associated with elevated liver enzymes.
No elevated liver enzyme content present in the provided label excerpts.
Tigecycline can cause liver damage.
No liver damage content present in the provided label excerpts.
Tigecycline was associated with a higher risk of liver damage compared to other antibiotics.
No comparative liver-damage risk information present in the provided label excerpts.
Tigecycline was associated with a significant increase in liver enzymes including alanine aminotransferase (ALT) and aspartate aminotransferase (AST).
No ALT/AST information present in the provided label excerpts.
The FDA states that tigecycline has been associated with cases of liver failure, including fatalities.
No liver failure/fatalities content present in the provided label excerpts.
The risk of liver damage during tigecycline therapy is higher in patients with pre-existing liver disease.
No liver disease risk stratification present in the provided label excerpts.
The risk of liver damage during tigecycline therapy is higher in patients taking other medications that can affect liver function.
No drug interaction/liver-function risk stratification content present in the provided label excerpts.
Liver function tests (LFTs) are blood tests that measure levels of various enzymes and proteins in the blood to assess liver health.
No definition/description of LFTs present in the provided label excerpts.
LFTs help diagnose liver damage.
No diagnostic use of LFTs content present in the provided label excerpts.
LFTs help monitor liver function.
No monitoring rationale content present in the provided label excerpts.
LFTs help detect liver disease.
No detection content present in the provided label excerpts.
LFTs should be performed before starting tigecycline therapy.
No baseline LFT instruction present in the provided label excerpts.
LFTs should be performed at least weekly during tigecycline treatment, according to the manufacturer's guidelines.
No LFT frequency instruction present in the provided label excerpts.
Experts recommend more frequent monitoring of LFTs during tigecycline therapy.
No expert recommendation content present in the provided label excerpts.
Some experts recommend daily LFTs in patients with pre-existing liver disease during tigecycline therapy.
No expert recommendation content present in the provided label excerpts.
Some experts recommend daily LFTs in patients taking other medications that can affect liver function during tigecycline therapy.
No expert recommendation content present in the provided label excerpts.
Liver damage during tigecycline therapy can manifest as elevated liver enzymes (ALT and AST).
No liver-damage clinical manifestations present in the provided label excerpts.
Liver damage during tigecycline therapy can manifest as jaundice.
No jaundice content present in the provided label excerpts.
Liver damage during tigecycline therapy can manifest as fatigue.
No liver-damage symptom content present in the provided label excerpts.
Liver damage during tigecycline therapy can manifest as loss of appetite.
No liver-damage symptom content present in the provided label excerpts.
Liver damage during tigecycline therapy can manifest as nausea and vomiting.
No liver-damage symptom content present in the provided label excerpts.
Liver damage during tigecycline therapy can manifest as abdominal pain.
No liver-damage symptom content present in the provided label excerpts.
Not monitoring liver function during tigecycline therapy can lead to liver failure.
No liver monitoring consequences content present in the provided label excerpts.
Not monitoring liver function during tigecycline therapy can lead to liver transplantation.
No liver transplantation consequences content present in the provided label excerpts.
Not monitoring liver function during tigecycline therapy can lead to death.
No liver monitoring/liver-failure-to-death consequence content present in the provided label excerpts.
Liver function tests are essential during tigecycline therapy to monitor for potential liver damage.
No label content on essential LFT monitoring for liver damage present in the provided label excerpts.
Healthcare professionals should be vigilant in monitoring LFTs during tigecycline therapy.
No label content on LFT vigilance during tigecycline therapy present in the provided label excerpts.
Healthcare professionals should adjust therapy accordingly to minimize the risk of liver damage during tigecycline therapy.
No label content on therapy adjustment based on LFTs/liver damage present in the provided label excerpts.
Contradictions
Low
AI Statement
The FDA states that tigecycline has been associated with cases of liver failure, including fatalities.
Label Reference
The provided label excerpts do not mention liver failure or fatalities; additionally, the provided boxed warning content concerns all-cause mortality imbalance, not liver failure.
Important Omissions
Boxed Warning / all-cause mortality information from the supplied label excerpts (e.g., adjusted risk difference 0.6%, deaths 4.0% vs 3.0% with comparator, and 'cause has not been established' / 'reserved when alternatives are not suitable') is not discussed in the provided AI statements.
Importance:
Moderate
Any label-supported guidance about indications/limitations of use (e.g., not indicated for hospital-acquired or ventilator-associated pneumonia) is not addressed.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluation is limited to alignment with the supplied label excerpts. The AI statements are largely unsupported by the provided label content (which contains only all-cause mortality-related warnings), so the risk assessment is driven by likelihood of misinformation rather than direct label conflict.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most liver-toxicity and liver-monitoring claims are not supported by the provided FDA label excerpts.
Suggested Improvement
Restrict claims to information present in the provided prescribing information (boxed warning/all-cause mortality and the supplied sections), or provide the relevant label sections covering hepatotoxicity/LFT monitoring before making those claims.